[1] |
Wu Y, Wang Y, Wang L, et al. Burden of melanoma in China, 1990⁃2017: findings from the 2017 global burden of disease study[J]. Int J Cancer, 2020,147(3):692⁃701. doi: 10.1002/ijc.32764.
|
[2] |
Manganoni AM, Pizzatti L, Pavoni L, et al. Melanoma in the elderly[J]. G Ital Dermatol Venereol, 2017,152(3):203⁃207. doi: 10.23736/S0392⁃0488.17.05609⁃7.
|
[3] |
Segura S, Podlipnik S, Boada A, et al. Melanoma⁃specific survival is worse in the elderly: a multicentric cohort study[J]. Melanoma Res, 2023,33(6):532⁃538. doi: 10.1097/CMR.0000 000000000923.
|
[4] |
Weiss SA, Han J, Darvishian F, et al. Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts[J]. J Transl Med, 2016,14(1):299. doi: 10.1186/s12967⁃016⁃1026⁃2.
|
[5] |
Buja A, Rugge M, Trevisiol C, et al. Cutaneous melanoma in older patients[J]. BMC Geriatr, 2024,24(1):232. doi: 10.1186/s12877⁃024⁃04806⁃8.
|
[6] |
Greene AC, Matzelle⁃Zywicki M, Ziegler O, et al. Characteristics and variations in young adults with cutaneous melanoma: a national cancer database analysis[J]. J Surg Oncol, 2024,129(8):1554⁃1565. doi: 10.1002/jso.27685.
|
[7] |
Mao L, Qi Z, Zhang L, et al. Immunotherapy in acral and mucosal melanoma: current status and future directions[J]. Front Immunol, 2021,12:680407. doi: 10.3389/fimmu.2021.680407.
|
[8] |
陈欣琪, 赵娟, 王朋, 等. 皮肤黑素瘤94例临床病理特点与基因突变的关系[J]. 中华皮肤科杂志, 2022,55(5):395⁃400. doi: 10.35541/cjd.20210433.
|
[9] |
张晓, 陈凤鸣, 柳琳, 等. Ⅰ期皮肤黑素瘤163例临床病理特征及预后分析[J]. 中华皮肤科杂志, 2022,55(5):389⁃394. doi: 10.35541/cjd.20210648.
|
[10] |
Fujisawa Y, Yoshikawa S, Minagawa A, et al. Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma[J]. Cancer Med, 2019,8(5):2146⁃2156. doi: 10.1002/cam4.2110.
|
[11] |
Oh Y, Choi S, Cho MY, et al. Male sex and Breslow thickness are important risk factors for recurrence of localized melanoma in Korean populations[J]. J Am Acad Dermatol, 2020,83(4):1071⁃1079. doi: 10.1016/j.jaad.2019.09.029.
|
[12] |
Purim K, Bonetti J, Silva J, et al. Characteristics of melanoma in the elderly[J]. Rev Col Bras Cir, 2020,47:e20202441. doi: 10.1590/0100⁃6991e⁃20202441.
|
[13] |
Ferhatoglu F, Erturk K, Faruk T. Cutaneous melanoma survival rates of the elderly are not worse than those of the young, yet they have some specific differences[J]. J Cancer Res Ther, 2023,19(Supplement):S0. doi: 10.4103/jcrt.jcrt_815_21.
|
[14] |
Buja A, Rugge M, Damiani G, et al. Sex differences in cutaneous melanoma: incidence, clinicopathological profile, survival, and costs[J]. J Womens Health (Larchmt), 2022,31(7):1012⁃1019. doi: 10.1089/jwh.2021.0223.
|
[15] |
Ciocan D, Barbe C, Aubin F, et al. Distinctive features of melanoma and its management in elderly patients: a population⁃based study in France[J]. JAMA Dermatol, 2013,149(10):1150⁃1157. doi: 10.1001/jamadermatol.2013.706.
|
[16] |
Tragos C, Hieken TJ. Optimizing the management of cutaneous melanoma in the elderly[J]. Surgery, 2011,150(4):828⁃835. doi: 10.1016/j.surg.2011.07.054.
|
[17] |
Behbahani S, Maddukuri S, Cadwell JB, et al. Gender differences in cutaneous melanoma: demographics, prognostic factors, and survival outcomes[J]. Dermatol Ther, 2020,33(6):e14131. doi: 10.1111/dth.14131.
|
[18] |
Maibach F, Sadozai H, Seyed Jafari SM, et al. Tumor⁃infiltrating lymphocytes and their prognostic value in cutaneous melanoma[J]. Front Immunol, 2020,11:2105. doi: 10.3389/fimmu.2020. 02105.
|
[19] |
Mishra K, Barnhill RL, Paddock LE, et al. Histopathologic variables differentially affect melanoma survival by age at diagnosis[J]. Pigment Cell Melanoma Res, 2019,32(4):593⁃600. doi: 10.1111/pcmr.12770.
|
[20] |
Alexandru Gata V, Milan Kubelac P, Buiga R, et al. The value of tumor infiltrating lymphocytes as prognostic factor for lymph node status and survival amongst patients with cutaneous malignant melanoma[J]. J BUON, 2020,25(6):2700⁃2707.
|
[21] |
Tas F, Erturk K. Coexistence of regression and tumor infiltrating lymphocytes is associated with more favorable survival in melanoma[J]. J Cancer Res Clin Oncol, 2021,147(9):2721⁃2729. doi: 10.1007/s00432⁃021⁃03565⁃y.
|
[22] |
Kane M, Holmes A, Kerr P, et al. Survival outcomes following immune checkpoint inhibitor therapy of advanced cutaneous melanoma by age and tumor infiltrating lymphocytes in the primary cutaneous site[J]. J Clin Oncol, 2022, 40(16_suppl):e21514⁃e21514. doi: 10.1200/jco.2022.40.16_suppl.e21514.
|
[23] |
Ben⁃Betzalel G, Steinberg⁃Silman Y, Stoff R, et al. Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients[J]. Eur J Cancer, 2019,108:61⁃68. doi: 10.1016/j.ejca.2018.12.012.
|
[24] |
Sasson DC, Smetona JT, Parsaei Y, et al. Malignant melanoma in older adults: different patient or different disease?[J]. Cureus, 2023,15(2):e34742. doi: 10.7759/cureus.34742.
|
[25] |
Ren M, Zhang J, Kong Y, et al. BRAF, C⁃KIT, and NRAS mutations correlated with different clinicopathological features: an analysis of 691 melanoma patients from a single center[J]. Ann Transl Med, 2022,10(2):31. doi: 10.21037/atm⁃21⁃4235.
|
[26] |
Candido S, Rapisarda V, Marconi A, et al. Analysis of the B⁃RafV600E mutation in cutaneous melanoma patients with occupational sun exposure[J]. Oncol Rep, 2014,31(3):1079⁃1082. doi: 10.3892/or.2014.2977.
|
[27] |
Piñero⁃Madrona A, Ruiz⁃Merino G, Cerezuela Fuentes P, et al. Mitotic rate as an important prognostic factor in cutaneous malignant melanoma[J]. Clin Transl Oncol, 2019,21(10):1348⁃1356. doi: 10.1007/s12094⁃019⁃02064⁃4.
|
[28] |
Huang K, Fan J, Misra S. Acral lentiginous melanoma: incidence and survival in the United States, 2006⁃2015, an analysis of the SEER registry[J]. J Surg Res, 2020,251:329⁃339. doi: 10.1016/j.jss.2020.02.010.
|
[29] |
Rees MJ, Liao H, Spillane J, et al. Localized melanoma in older patients, the impact of increasing age and comorbid medical conditions[J]. Eur J Surg Oncol, 2016,42(9):1359⁃1366. doi: 10.1016/j.ejso.2016.01.010.
|
[30] |
Sun J, Zhou JS, Wang YC, et al. Prognostic significance of age on superficial spreading melanoma after resection: lessons from SEER database involving 12 536 patients[J]. ANZ J Surg, 2023,93(1⁃2):227⁃234. doi: 10.1111/ans.18135.
|
[31] |
Woo TE, Stukalin I, Ding PQ, et al. Effectiveness of immune checkpoint inhibitor with anti⁃PD⁃1 monotherapy or in combination with ipilimumab in younger versus older adults with advanced melanoma[J]. Curr Oncol, 2023,30(10):8936⁃8947. doi: 10.3390/curroncol30100646.
|
[32] |
Bateni SB, Johns AJ, Gingrich AA, et al. Elderly age is associated with more conservative treatment of invasive melanoma[J]. Anticancer Res, 2020,40(5):2895⁃2903. doi: 10. 21873/anticanres.14266.
|
[33] |
Jochems A, Bastiaannet E, Aarts M, et al. Outcomes for systemic therapy in older patients with metastatic melanoma: results from the Dutch Melanoma Treatment Registry[J]. J Geriatr Oncol, 2021,12(7):1031⁃1038. doi: 10.1016/j.jgo.2021.04.006.
|
[34] |
Mattila KE, Vihinen H, Heervä E, et al. The impact of prognostic factors and comorbidities on survival in older adults with stageⅠ⁃Ⅲ cutaneous melanoma in Southwest Finland: a register study[J]. J Geriatr Oncol, 2024,15(2):101701. doi: 10.1016/j.jgo. 2023.101701.
|